Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy

European Cytokine Network

Volumn 17, Issue 3, 2006, Pages 155-165

  Abu El Asrar, Ahmed M ^a   Struyf, Sofie ^b   Kangave, Dustan ^a   Geboes, Karel ^c   Van Damme, Jo ^b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Chemokines; Diabetic retinopathy; Eye; Proliferative vitreoretinopathy; Retina; Vitreous humor

Indexed keywords

CHEMOKINE;

ADULT; ARTICLE; BLOOD; DIABETIC RETINOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; VITREORETINOPATHY; VITREOUS BODY;

ADULT; CHEMOKINES; DIABETIC RETINOPATHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; VITREORETINOPATHY, PROLIFERATIVE; VITREOUS BODY;

EID: 39049193307     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Esser P, Heimann K, Wiedemann P. Macrophages in proliferative vitreoretinopathy and proliferative diabetic retinopathy: differentiation of subpopulations. Br J Ophthalmol 1993; 77: 731-3.
2. Tang S, Le-Ruppert KC. Activated T lymphocytes in epiretinal membranes from eyes of patients with proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 1995; 233: 21-5.
3. Charteris DG, Hiscott P, Grierson I, Lightman SL. Proliferative vitreoretinopathy: lymphocytes in periretinal membranes. Ophthalmology 1992; 99: 1364-7.
4. Capeans C, De Rojas MV, Lojo S, Salorio MS. C-C chemokines in the vitreous of patients with proliferative vitreoretinopathy and proliferative diabetic retinopathy. Retina 1998; 18: 546-50.
5. Elner SG, Elner VM, Jaffe GJ, Stuart A, Kunkel SL, Strieter RM. Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr Eye Res 1995; 14: 1045-53.
6. Abu El-Asrar AM, Van Damme J, Put W, Veckeneer M, Dralands L, Billiau A, Missotten L. Monocyte chemotactic protein-1 in proliferative vitreoretinal disorders. Am J Ophthalmol 1997; 123: 599-606.
7. Brooks Jr. HL, Caballero Jr. S, Newell CK, Steinmetz RL, Watson D, Segal MS, Harrison JK, Scott EW, Grant MB. Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch Ophthalmol 2004; 122: 1801-7.
8. Elner SG, Strieter R, Bian ZM, Kunkel S, Mokhtarzaden L, Johnson M, Lukacs N, Elner VM. Interferon-induced protein 10 and interleukin 8: C-X-C chemokines present in proliferative diabetic retinopathy. Arch Ophthalmol 1998; 116: 1597-601.
9. Miller JW, Adamis AP, Aiello LP. Vascular endothelial growth factor in ocular neovascularization and proliferative retinopathy. Diabetes Metab Rev 1997; 13: 37-50.
10. Watanabe D, Suzuma K, Kurimoto M, Kiryu J, Kita M, Suzuma I, Ohashi H, Ojima T, Murkami T, Kobayashi T, Masua S, Nagao M, Yoshimura N, Tkagi H. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005; 353: 782-92.
11. Struyf S, Proost P, Van Damme J. Regulation of the immune response by the interaction of chemokines and proteases. Adv Immunol 2003; 81: 1-44.
12. Salcedo R, Oppenheim JJ. Role of chemokines in angiogenesis: CXCL12/ SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation 2003; 10: 359-70.
13. Agostini C, Gurrieri C. Chemokine/cytokine cocktail in idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006; 3: 357-63.
14. Ong VH. Evans La, Shiwen X, Fisher IB, Rajkumar V, Abraham DJ, Black CM, Denton CP. Monocyte chemoattractant protein 3 as amediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tight-skin mouse. Arthritis Rheum 2003; 48: 1979-91.
15. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, Power CA. International Union of Pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000; 52: 145-76.
16. Mirshahi F, Pourtau J, Li H, Muraine M, Trochon V, Legrand E, Vannier J-P, Soria J, Vasse N, Soria C. SDF-1 activity on microvascular endothelial cells: consequences on angiogenesis in in vitro and in vivo models. Thromb Res 2000; 99: 587-94.
17. Salvucci O, Yao L, Villalba S, Sajewicz A, Pittaluga S, Tosato G. Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. Blood 2002; 99: 2703-11.
18. Kryczek I, Lange A, Mottram P, Alvarez X, Cheng P, Hogan M, Moons L, Wei S, Zou L, Machelon V, Emilie D, Terrassa M, Lackner A, Curiel TJ, Carmeliet P, Zou W. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res 2005; 65: 465-72.
19. Retina Society Terminology Committee. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 1983; 90: 121-5.
20. Struyf S, Van Collie E, Paemen L, Paemen L, Put W, Lenaerts JP, Proost P, Opdenakker G, Van Damme J. Synergistic induction of MCP-1 and -2 by IL-1 beta and interferons in fibroblasts and epithelial cells. J Leukoc Biol 1998; 63: 364-72.
21. Proost P, Van Leuven P, Wuyts A, Ebberink R, Opdenakker G, Van Damme J. Chemical synthesis, purification and folding of the human monocyte chemotactic proteins MCP-2 and MCP-3 into biologically active chemokines. Cytokine 1995; 7: 97-104.
22. Van Coillie E, Proost P, Van Aelst L, Struyf S, Polfliet M, De Meester I, Harvey DJ, Van Damme J, Opdenakker G. Functional comparison of two human monocyte chemotactic protein-2 isoforms, role of the amino-terminal pyroglutamic acid and processing by CD26/dipeptidyl peptidase IV. Biochemistry 1998; 37: 12672-80.
23. Wuyts A, Van Osselaer N, Haelens A, Samson I, Herdewijn P, Ben-Baruch A, Oppenheim JJ, Proost P, Van Damme J. Characterization of synthetic human granulocyte chemotactic protein 2: usage of chemokine receptors CXCR1 and CXCR2 and in vivo inflammatory properties. Biochemistry 1997; 36: 2716-23.
24. Belperio JA, Keane MP, Burdick MD, Lynch III JP, Xue YY, Berlin A, Ross DJ, Kunkel SL, Charo IF, Strieter RM. Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis syndrome. J Clin Invest 2001; 108: 547-56.
25. Inoshima I, Kuwano K, Hamada N, Hagimoto N, Yoshimi M, Maeyama T, Takeshita A, Kitamoto S, Egashira K, Hara N. Antimonocyte chemoattractant protein-1 gene therapy attenuates pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 2004; 286: L1038-L1044.
26. Wada T, Furuichi K, Sakai N, Iwata Y, Kitagawa K, Ishida Y, Kondo T, Hashimoto H, Ishiwata Y, Mukaida N, Tomosugi N, Matsushima K, Egashira K, Yokoyama H. Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis. J Am Soc Nephrol 2004; 15: 940-8.
27. Low QE, Drugea IA, Duffner LA, Quinn DG, Cook DN, Rollins BJ, Kovacs EJ, DiPietro LA. Wound healing in MIP-1 alpha (-/-) and MCP-1 (-/-) mice. Am J Pathol 2001; 159: 457-63.
28. Gharaee-Kermani M, Denholm EM, Phan SH. Costimulation of fibroblast collagen and transforming growth factor b1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996; 271: 17779-84.
29. Hong KH, Ryu J, Han KH. Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A. Blood 2005; 105: 1405-7.
30. Salcedo R, Ponce ML, Young HA, Wasserman YK, Ward JM, Kleinman HK, Oppenheim JJ, Murphy WJ. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000; 96: 34-40.
31. Kim MY, Byeon CW, Hong KH, Han KH, Jeong S. Inhibition of angiogenesis by the MCP-1 (monocyte chemoattractant protein-1) binding peptide. FEBS Lett 2005; 579: 1597-601.
32. Yosida S, Yosida A, Ishibashi T, Elner SG, Elner VM. Role of MCP-1 and MIP-1 alpha in retinal neovascularization during post ischemic inflammation in amouse model of retinal neovascularization. J Leukoc Biol 2003; 73: 137-44.
33. Feng L, Matsumoto C, Schwartz A, Schmidt AM, Stern DM, Pile-Spellman J. Chronic vascular inflammation in patients with type 2 diabetes. Diabetes Care 2005; 28: 379-84.
34. Kowluru RA. Retinal metabolic abnormalities in diabetic mouse: comparison with diabetic rat. Curr Eye Res 2002; 24: 123-8.
35. Stitt AW. The role of advanced glycation in the pathogenesis of diabetic retinopathy. Exp Mol Pathol 2003; 75: 95-108.
36. Lakshminarayanan V, Lewallen M, Frangogiannis NG, Evans AI, Wedin KE, Michael LH, Entman ML. Reactive oxygen intermediates induce monocyte chemotactic protein-1 in vascular endothelium after brief ischemia. Am J Pathol 2001; 159: 1301-11.
37. Inagaki Y, Yamagishi S, Okamoto T, Takeuchi M, Amano S. Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation. Diabetologia 2003; 46: 284-7.
38. Takaishi H, Taniguchi T, Takahashi A, Ishikawa Y, Yokoyama M. High glucose accelerates MCP-1 production via p38 MAPK in vascular endothelial cells. Biochem Biophys Res Commun 2003; 305: 122-8.
39. Yamada M, Kim S, Egashira K, Takeya M, Ikeda T, Mimura O, Iwao H. Molecular mechanism and role of endothelial monocyte chemoattractant protein-1 induction by vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 2003; 23: 1996-2001.
40. Ceradini DJ, Gurtner GC. Homing to hypoxia: HIF-1 as a mediator of progenitor cell recruitment to injured tissue. Trends Cardiovasc Med 2005; 15: 57-63.
41. Bochaton-Piallat M-L, Kapetanios AD, Donati G, Redard M, Gabbiani G, Pournaras CJ. TGF-β1, TGF-β receptor II and ED-A fibronectin expression in myofibroblast of vitreoretinopathy. Invest Ophthalmol Vis Sci 2000; 41: 2336-42.
42. Boitelle A, Gosset P, Capin MC, Vanhee D, Marquette CH, Wallaert B, Gosselin B, Tonnel AB. MCP-1 secretion in lung from nonsmoking patients with coal worker's pneumoconiosis. Eur Respir J 1997; 10: 557-62.
43. Yamamoto T, Eckes B, Hartmann K, Krieg T. Expression of monocyte chemoattractant protein-1 in the lesional skin of systemic sclerosis. J Dermatol Sci 2001; 26: 133-9.
44. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121: 335-48.
45. Hitchon C, Wong K, Ma G, Reed J, Lyttle D, El-Gabalawy H. Hypoxia-induced production of stromal cell-derived factor 1 (CXCL12) and vascular endothelial growth factor by synovial fibroblasts. Arthritis Rheum 2002; 46: 2587-97.
46. + T cell migration within synovial tissue. Arthritis Rheum 2003; 48: 2472-82.
47. Boulday G, Haskova Z, Reinders ME, Pal S, Briscoe DM. Vascular endothelial growth factor induced signaling pathways in endothelial cells that mediate overexpression of the chemokines IFN-gamma-inducible protein of 10KDa in vitro and in vivo. J Immunol 2006; 176: 3098-107.
48. Tayer AM, Kradin RL, LaCamera P, Bercury SD, Campanella GS, Leary CP, Polosukhin V, Zhao LH, Sakamoto H, Blackwell TS, Luster AD. Inhibition of pulmonary fibrosis by the chemokine IP-10/CXCL10. Am J Respir Cell Mol Biol 2004; 31: 395-404.
49. Suzuki K, Kanabayashi T, Nakayama H, Doi K. Kinetics of chemokines and their receptors in mercuric chloride-induced tubulointerstitial lesions in Brown Norway rats. Exp Mol Pathol 2003; 75: 58-67.
50. Marstik M, Kotseos K, Chunfeng MA, Chegini N. Increased expression of interferon-inducible protein-10 during surgically induced peritoneal injury. Wound Rep Reg 2003; 11: 120-6.
51. Keane MP, Belperio JA, Arenberg DA, Burdick MD, Zu ZJ, Xue YY, Strieter RM. IFN-γ-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J Immunol 1999; 163: 5686-92.
52. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, Dzuiba J, Van Damme J, Walz A, Marriott D, Chan S-Y, Roczniak S, Shanafelt AB. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995; 270: 27348-57.
53. Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S, Kleinman HK, Reaman GH, Tosato G. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995; 182: 155-62.
54. Struyf S, Burdick MD, Proost P, Van Damme J, Strieter RM. Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/ CXCL4 and potent inhibitor of angiogenesis. Circ Res 2004; 95: 855-7.
55. Proost P, Schutyser E, Menten P, Struyf S, Wuyts A, Opdenakker G, Detheux M, Parmentier M, Durinx C, Lambeir AM, Neyts J, Liekens S, Maudgal PC, Billiau A, Van Damme J. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood 2001; 98: 3554-61.